Abstract
Coactivator activator (CoAA) is a dual-functional coregulator that regulates steroid receptor-mediated transcription and alternative splicing. Previously, we have shown that CoAA has tumor-suppressive potential in tumorigenic human kidney cells. Here, we uncover a molecular mechanism by which Sjogren syndrome-associated autoantigen (SSA), an estrogen receptor (ER) coactivator, induces MYC oncogene by removing repressive CoAA through E2-dependent degradation of CoAA and promotes G 1 /S transition of the cell cycle as well as anchorage-independent growth capability of breast cancer cells. We also show that E2 and ER enhance the E3 ligase activity of SSA to modulate CoAA through splicing isoform-selective ubiquitylation. We propose this as one potential molecular basis for the reduced tumor incidence in autoimmune disease patients and suggest SSA as a potential therapeutic target to treat breast cancer. © 2014, American Society for Microbiology.
Cite
CITATION STYLE
Kang, Y. K., Jung, S. Y., Qin, J., Li, C., Tsai, S. Y., Tsai, M.-J., & O’Malley, B. W. (2014). E2/Estrogen Receptor/Sjogren Syndrome-Associated Autoantigen Relieves Coactivator Activator-Induced G 1 /S Arrest To Promote Breast Tumorigenicity. Molecular and Cellular Biology, 34(9), 1670–1681. https://doi.org/10.1128/mcb.01564-13
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.